JURJ, A., C. POP-BICA, Ondřej SLABÝ, C. D. STEFAN, W. C. CHO, S. S. KORBAN and I. BERINDAN-NEAGOE. Tiny Actors in the Big Cellular World: Extracellular Vesicles Playing Critical Roles in Cancer. International Journal of Molecular Sciences. Basel: Multidisciplinary Digital Publishing Institute, 2020, vol. 21, No 20, p. 1-27. ISSN 1422-0067. Available from: https://dx.doi.org/10.3390/ijms21207688.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Tiny Actors in the Big Cellular World: Extracellular Vesicles Playing Critical Roles in Cancer
Authors JURJ, A. (642 Romania), C. POP-BICA (642 Romania), Ondřej SLABÝ (203 Czech Republic, belonging to the institution), C. D. STEFAN (702 Singapore), W. C. CHO (156 China), S. S. KORBAN (840 United States of America) and I. BERINDAN-NEAGOE (642 Romania, guarantor).
Edition International Journal of Molecular Sciences, Basel, Multidisciplinary Digital Publishing Institute, 2020, 1422-0067.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 10608 Biochemistry and molecular biology
Country of publisher Switzerland
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 5.923
RIV identification code RIV/00216224:14110/20:00117881
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.3390/ijms21207688
UT WoS 000585581600001
Keywords in English extracellular vesicles; cancer; therapeutic agents; cell-to-cell communication
Tags 14110230, podil, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 21/7/2021 10:28.
Abstract
Communications among cells can be achieved either via direct interactions or via secretion of soluble factors. The emergence of extracellular vesicles (EVs) as entities that play key roles in cell-to-cell communication offer opportunities in exploring their features for use in therapeutics; i.e., management and treatment of various pathologies, such as those used for cancer. The potential use of EVs as therapeutic agents is attributed not only for their cell membrane-bound components, but also for their cargos, mostly bioactive molecules, wherein the former regulate interactions with a recipient cell while the latter trigger cellular functions/molecular mechanisms of a recipient cell. In this article, we highlight the involvement of EVs in hallmarks of a cancer cell, particularly focusing on those molecular processes that are influenced by EV cargos. Moreover, we explored the roles of RNA species and proteins carried by EVs in eliciting drug resistance phenotypes. Interestingly, engineered EVs have been investigated and proposed as therapeutic agents in various in vivo and in vitro studies, as well as in several clinical trials.
Links
824036, interní kód MUName: Excellence in research and development of non-coding RNA DIAGnostics in ONcology (Acronym: RNADIAGON)
Investor: European Union, MSCA Marie Skłodowska-Curie Actions (Excellent Science)
PrintDisplayed: 28/5/2024 19:14